PDS Biotechnology Corporation

NASDAQ:PDSB   3:59:52 PM EDT
3.70
+0.05 (+1.37%)
Products, Regulatory

Pds Biotech Announces Presentation Of Data From Nci-Led Triple Combination Phase 2 Clinical Trial In Advanced, Refractory Hpv-Positive Cancers At Asco 2022

Published: 05/26/2022 23:57 GMT
PDS Biotechnology Corporation (PDSB) - Pds Biotech Announces Presentation of Data From Nci-led Triple Combination Phase 2 Clinical Trial in Advanced, Refractory Hpv-positive Cancers at Asco 2022.
Pds Biotechnology Corp - 77% of Checkpoint Inhibitor (cpi) Refractory Patients Alive at Median Follow Up of 12 Months.
Pds Biotechnology Corp - 75% of Cpi NaÏve Patients Alive at Median Follow Up of 17 Months.
Pds Biotechnology Corp - Anti-tumor Objective Responses Seen in 88% of Cpi NaÏve Patients and 63% Cpi Refractory Patients (high Dose of M9241).